Ocular Hypertension Pipeline Forecast 2024: FDA Approvals, Therapies, Mechanism of Action, Route of Administration, and Developments | Laboratoires Thea, Rigshospitalet, Amneal Pharmaceuticals, Theratocular Biotek Co., Alcon Research, Otsuka Beijing Resea

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Ocular Hypertension pipeline constitutes 70+ key companies continuously working towards developing 75+ Ocular Hypertension treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Ocular Hypertension Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Ocular Hypertension Market.

The Ocular Hypertension Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Ocular Hypertension Pipeline Report: https://www.delveinsight.com/sample-request/ocular-hypertension-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Ocular Hypertension treatment therapies with a considerable amount of success over the years.
• Ocular Hypertension companies working in the treatment market are Laboratoires Thea, Rigshospitalet, Amneal Pharmaceuticals, Theratocular Biotek Co., Alcon Research, Otsuka Beijing Research Institute, Qlaris Bio, Inc., Nicox Ophthalmics, Ocuphire Pharma, Santen Inc., Ono Pharmaceutical, MediPrint Ophthalmics, Visiox Pharma, Sun Pharma Advanced Research Company, JeniVision, Inc., Glaukos Corporation, D. Western Therapeutics Institute, Inc., AbbVie, TearClear Corp, Ocular Therapeutix, Inc., Perfuse Therapeutics, Inc., and others, are developing therapies for the Ocular Hypertension treatment
• Emerging Ocular Hypertension therapies in the different phases of clinical trials are- LUMIGAN®, TO-O-1001, AR-17043, OPC-1085EL, QLS-111, NCX 470, Nyxol, Sepetaprost(DE-126/ONO-9054/STN1012600 ), LL-BMT1, PDP-716, V-GL1, NCX 470, Kinezodianone R hydrochloride, G2-TR intraocular implant containing travoprost, H-1337, AGN-193408 SR, Latanoprost ophthalmic solution, OTX-TIC, PER-001, and others are expected to have a significant impact on the Ocular Hypertension market in the coming years.
• In November 2024, MediPrint® Ophthalmics, a clinical-stage ophthalmic drug delivery company based in San Diego, has announced the results of its Phase 2b clinical trial for LL-BMT1. Utilizing an innovative 3D-printed, drug-eluting contact lens designed for sustained delivery of bimatoprost and hyaluronic acid, the trial successfully met all Phase 2b endpoints. Presented by Dr. Ian Ben Gaddie at the American Academy of Optometry's annual meeting in Indianapolis, the findings highlighted LL-BMT1's potential as a groundbreaking solution for managing mild to moderate glaucoma while enhancing contact lens comfort by alleviating dry eye symptoms.
• In April 2024, Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company dedicated to improving vision and quality of life through innovative treatments for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other eye disorders, has announced positive Phase 2 results for PAXTRAVA (travoprost intracameral implant or OTX-TIC) in patients with open-angle glaucoma or ocular hypertension.

Ocular Hypertension Overview
Ocular hypertension refers to elevated intraocular pressure (IOP) within the eye that exceeds the normal range, typically above 21 mmHg, without causing detectable damage to the optic nerve or vision loss. It is a significant risk factor for developing glaucoma, particularly open-angle glaucoma. Ocular hypertension occurs when the eye's aqueous humor drainage is impaired, leading to increased fluid buildup and pressure. Common risk factors include age, family history, thin corneas, and certain medications. Early detection and management are crucial to prevent progression to glaucoma, often involving regular monitoring and medications to lower IOP.

Get a Free Sample PDF Report to know more about Ocular Hypertension Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/ocular-hypertension-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Ocular Hypertension Drugs Under Different Phases of Clinical Development Include:
• T4090: Laboratoires Thea
• Xalatan: Rigshospitalet
• Reference - LUMIGAN®: Amneal Pharmaceuticals
• TO-O-1001: Theratocular Biotek Co.
• AR-17043: Alcon Research
• OPC-1085EL: Otsuka Beijing Research Institute
• QLS-111: Qlaris Bio, Inc.
• NCX 470: Nicox Ophthalmics
• Nyxol: Ocuphire Pharma
• Sepetaprost(DE-126/ONO-9054/STN1012600 ): Santen Inc. /Ono Pharmaceutical
• LL-BMT1: MediPrint Ophthalmics
• PDP-716: Visiox Pharma/ Sun Pharma Advanced Research Company
• JV-GL1: JeniVision, Inc.
• NCX 470: Nicox Ophthalmics, Inc.
• Kinezodianone R hydrochloride: Laboratoires Thea
• G2-TR intraocular implant containing travoprost: Glaukos Corporation
• H-1337: D. Western Therapeutics Institute, Inc.
• AGN-193408 SR: AbbVie
• Latanoprost ophthalmic solution: TearClear Corp
• OTX-TIC: Ocular Therapeutix, Inc.
• PER-001: Perfuse Therapeutics, Inc.

Ocular Hypertension Route of Administration
Ocular Hypertension pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Ocular Hypertension Molecule Type
Ocular Hypertension Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Ocular Hypertension Pipeline Therapeutics Assessment
• Ocular Hypertension Assessment by Product Type
• Ocular Hypertension By Stage and Product Type
• Ocular Hypertension Assessment by Route of Administration
• Ocular Hypertension By Stage and Route of Administration
• Ocular Hypertension Assessment by Molecule Type
• Ocular Hypertension by Stage and Molecule Type
DelveInsight's Ocular Hypertension Report covers around 75+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Ocular Hypertension product details are provided in the report. Download the Ocular Hypertension pipeline report to learn more about the emerging Ocular Hypertension therapies at:
https://www.delveinsight.com/sample-request/ocular-hypertension-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Ocular Hypertension Therapeutics Market include:
Key companies developing therapies for Ocular Hypertension are - JeniVision, Inc., Nicox Ophthalmics, Inc., Laboratoires Thea, Glaukos Corporation, D. Western Therapeutics Institute, Inc., AbbVie, TearClear Corp, Ocular Therapeutix, Inc., Perfuse Therapeutics, Inc., and others.

Ocular Hypertension Pipeline Analysis:
The Ocular Hypertension pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Ocular Hypertension with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Ocular Hypertension Treatment.
• Ocular Hypertension key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Ocular Hypertension Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Ocular Hypertension market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Ocular Hypertension drugs and therapies-
https://www.delveinsight.com/sample-request/ocular-hypertension-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Ocular Hypertension Pipeline Market Drivers
• Growing Prevalence, Advancements in Research, Rising Awareness, Regulatory Support, Investment in R&D, are some of the important factors that are fueling the Ocular Hypertension Market.

Ocular Hypertension Pipeline Market Barriers
• However, High Development Costs, Regulatory Challenges, Limited Patient Compliance, Competitive Landscape, Healthcare Access Disparities, and other factors are creating obstacles in the Ocular Hypertension Market growth.

Scope of Ocular Hypertension Pipeline Drug Insight
• Coverage: Global
• Key Ocular Hypertension Companies: Laboratoires Thea, Rigshospitalet, Amneal Pharmaceuticals, Theratocular Biotek Co., Alcon Research, Otsuka Beijing Research Institute, Qlaris Bio, Inc., Nicox Ophthalmics, Ocuphire Pharma, Santen Inc., Ono Pharmaceutical, MediPrint Ophthalmics, Visiox Pharma, Sun Pharma Advanced Research Company, JeniVision, Inc., Glaukos Corporation, D. Western Therapeutics Institute, Inc., AbbVie, TearClear Corp, Ocular Therapeutix, Inc., Perfuse Therapeutics, Inc., and others
• Key Ocular Hypertension Therapies: LUMIGAN®, TO-O-1001, AR-17043, OPC-1085EL, QLS-111, NCX 470, Nyxol, Sepetaprost(DE-126/ONO-9054/STN1012600 ), LL-BMT1, PDP-716, V-GL1, NCX 470, Kinezodianone R hydrochloride, G2-TR intraocular implant containing travoprost, H-1337, AGN-193408 SR, Latanoprost ophthalmic solution, OTX-TIC, PER-001, and others
• Ocular Hypertension Therapeutic Assessment: Ocular Hypertension current marketed and Ocular Hypertension emerging therapies
• Ocular Hypertension Market Dynamics: Ocular Hypertension market drivers and Ocular Hypertension market barriers

Request for Sample PDF Report for Ocular Hypertension Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/ocular-hypertension-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Ocular Hypertension Report Introduction
2. Ocular Hypertension Executive Summary
3. Ocular Hypertension Overview
4. Ocular Hypertension- Analytical Perspective In-depth Commercial Assessment
5. Ocular Hypertension Pipeline Therapeutics
6. Ocular Hypertension Late Stage Products (Phase II/III)
7. Ocular Hypertension Mid Stage Products (Phase II)
8. Ocular Hypertension Early Stage Products (Phase I)
9. Ocular Hypertension Preclinical Stage Products
10. Ocular Hypertension Therapeutics Assessment
11. Ocular Hypertension Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Ocular Hypertension Key Companies
14. Ocular Hypertension Key Products
15. Ocular Hypertension Unmet Needs
16 . Ocular Hypertension Market Drivers and Barriers
17. Ocular Hypertension Future Perspectives and Conclusion
18. Ocular Hypertension Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Ocular Hypertension Market https://www.delveinsight.com/report-store/ocular-hypertension-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Ocular Hypertension Market Insights, Epidemiology, and Market Forecast-2034' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Ocular Hypertension Epidemiology https://www.delveinsight.com/report-store/ocular-hypertension-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Ocular Hypertension Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:
• Transcatheter Heart Valve Replacement Devices Market: https://www.delveinsight.com/report-store/transcatheter-aortic-valve-replacement-market
• Bone Neoplasms Market: https://www.delveinsight.com/blog/bone-cancer-treatment-market
• Peak Flow Meters Market: https://www.delveinsight.com/report-store/peak-flow-meters-market
• Neuroendoscopy Market: https://www.delveinsight.com/report-store/neuroendoscopy-market
• Nosocomial Infections Market: https://www.delveinsight.com/report-store/nosocomial-infections-market
• Ophthalmic Imaging Equipment Market: https://www.delveinsight.com/report-store/ophthalmic-imaging-equipment-market

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.